The Watchman is a small, parachute-shaped device implanted in the heart to prevent strokes in people with atrial fibrillation. It works by permanently sealing off a small pouch in the heart called the left atrial appendage, where roughly 90% of stroke-causing blood clots form in people with this condition. Once sealed, the goal is to eliminate the need for long-term blood thinners.
Why the Left Atrial Appendage Matters
In a healthy heart, blood flows smoothly through all four chambers. Atrial fibrillation disrupts that rhythm, causing the upper chambers to quiver instead of contracting fully. This irregular motion lets blood pool and stagnate, particularly in the left atrial appendage, a small, finger-shaped pouch attached to the left atrium. That pooled blood can clot, and if a clot breaks free and travels to the brain, it causes a stroke.
The standard treatment has long been blood-thinning medications like warfarin, which reduce clotting throughout the entire body. These drugs work well, but they carry a constant risk of serious bleeding, especially for older adults, people prone to falls, or those with a history of major bleeds. The Watchman offers a different approach: rather than thinning the blood everywhere, it physically closes off the one spot where dangerous clots are most likely to form.
How the Device Seals the Appendage
The Watchman is built on a frame of nitinol, a flexible metal alloy that can compress for delivery and then spring back to its intended shape once released. The frame has 10 tiny anchors that grip the walls of the appendage and hold the device in place. Covering one end of the frame is a fabric cap made of a dense polymer mesh. This cap faces the main chamber of the left atrium after placement, acting as a barrier that blocks blood from entering the appendage.
Doctors choose a device size that’s 8% to 20% larger than the opening of the appendage. This intentional oversizing ensures the device compresses slightly against the walls, creating a snug fit and stable positioning. The newest version, the Watchman FLX Pro, comes in six sizes ranging from 20 mm to 40 mm and features a special coating designed to promote faster tissue growth and reduce the risk of clots forming on the device itself.
What Happens During the Procedure
The implant is done through a catheter, so there’s no open-heart surgery involved. A doctor makes a small incision in the femoral vein near the top of your leg and threads a thin, flexible tube up through the vein to your heart. To reach the left atrium, the catheter passes through a natural wall between the two upper chambers (a technique called transseptal puncture). The Watchman is loaded inside the catheter, guided into the left atrial appendage, and released. Its tiny hooks latch onto the appendage wall.
Advanced imaging confirms the device is firmly attached and completely covers the appendage opening. If placement looks good, the catheter is withdrawn and the small leg incision is closed. Most patients go home the next day.
How Your Body Grows Over the Device
The fabric cap isn’t meant to work alone forever. It serves as a scaffold for your body’s own tissue to grow over. Within three days of implantation, a layer of fibrin (a natural clotting protein) deposits on the surface and begins sealing gaps between the device and the heart wall. By about 45 days, a layer of cells identical to the ones lining the inside of your heart covers the entire surface. By 90 days, a complete natural lining has formed over what used to be the appendage opening, and the device is essentially incorporated into the heart wall.
This tissue growth is the reason the Watchman can eventually replace blood thinners entirely. Once the body’s own lining seals the appendage, there’s no exposed surface where clots can form and no opening for blood to pool in.
The Medication Transition After Implantation
You won’t stop blood thinners immediately after the procedure. During those first 45 days while tissue grows over the device, you’ll typically take a short course of a blood thinner (often a newer oral anticoagulant like apixaban or rivaroxaban) along with low-dose aspirin. An alternative regimen approved by the FDA uses two antiplatelet drugs together for 45 days instead of a full blood thinner, which may be preferable if bleeding risk is a major concern.
At the 45-day mark, your doctor will check the device with an imaging study to confirm it’s well-sealed. A successful result means no gap at all between the device and the heart wall, though small leaks of 5 mm or less are common and generally not considered dangerous. Leaks larger than 5 mm may require additional monitoring or treatment. If the seal looks good, you’ll transition off the blood thinner and typically take only aspirin and one additional antiplatelet drug for a few more months. After about six months total, most patients take nothing more than daily aspirin, and some eventually stop that too.
How It Compares to Blood Thinners
The strongest evidence comes from long-term follow-up data averaging nearly four years. Compared to warfarin, the Watchman reduced the combined risk of stroke, blood clots traveling to other organs, and cardiovascular death by 40%. The safety advantage was even more pronounced: the rate of major bleeding events dropped by more than 60% compared to staying on warfarin long-term. These results make sense when you consider that the device eliminates the need for a drug whose primary side effect is uncontrolled bleeding.
Risks of the Procedure
Like any heart procedure, implantation carries some risk. The most common serious complication is pericardial effusion, a buildup of fluid around the heart that sometimes requires drainage. This occurs in about 1.2% of cases. The broader category of major complications, including stroke during the procedure, significant bleeding, and vascular injury at the leg access site, occurs in roughly 6% of patients. These rates have improved over time as the device design and implantation techniques have evolved, and the vast majority of complications are treatable.
Who Is a Candidate
The Watchman isn’t for everyone with atrial fibrillation. The FDA approved it for people who have an elevated stroke risk and are suitable for blood thinners but have a good reason to seek an alternative. For insurance coverage, patients generally need a stroke risk score above a specific threshold and must be poor candidates for staying on blood thinners long-term.
In practice, the most common reasons doctors recommend the device are high stroke risk combined with a history of major bleeding (reported in about 64% of cases), a high risk of falls (36%), or strong patient preference to get off blood thinners (34%). Less common but still valid reasons include difficulty keeping blood-thinner levels stable or trouble taking medications consistently. The device is specifically designed for non-valvular atrial fibrillation, meaning it’s not used for people whose irregular heartbeat is caused by a problem with the heart valves themselves.